Cargando…

The Utility of Renal Mass Biopsy in Large Renal Masses

OBJECTIVES: The role of needle core renal biopsy in large renal masses, defined as lesions larger than 4 cm, is debatable, as larger renal masses are associated with malignant histology. We aim to review the safety and impact of renal biopsy on the management of large renal masses. METHODS: A retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Chau, Matthew, Thia, Ivan, Saluja, Manmeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474854/
https://www.ncbi.nlm.nih.gov/pubmed/37663006
http://dx.doi.org/10.2147/RRU.S404998
_version_ 1785100593929388032
author Chau, Matthew
Thia, Ivan
Saluja, Manmeet
author_facet Chau, Matthew
Thia, Ivan
Saluja, Manmeet
author_sort Chau, Matthew
collection PubMed
description OBJECTIVES: The role of needle core renal biopsy in large renal masses, defined as lesions larger than 4 cm, is debatable, as larger renal masses are associated with malignant histology. We aim to review the safety and impact of renal biopsy on the management of large renal masses. METHODS: A retrospective, single-center review of all renal biopsies performed between January 2011 and December 2020 at Royal Perth Hospital was conducted. Indications for biopsy, complications and final management plans were correlated to assess the value of biopsies in large renal masses. RESULTS: In total, 126 biopsies were performed. Indeterminate imaging findings and comorbidities were the main indications for biopsies. We identified 116 (92.1%) diagnostic biopsies and 10 (8.0%) non-diagnostic biopsies due to insufficient samples or inflammatory tissue. Of the diagnostic biopsies, 99 (78.6%) were malignant and 17 (13.5%) were benign. Unnecessary extirpative surgery was avoided in 17 patients. Histology included renal cell carcinoma (96%) and other malignancies such as urothelial carcinoma (3%) and non-Hodgkin’s lymphoma (1%). Benign biopsies identified histology including angiomyolipoma (35.3%) and oncocytoma (52.5%). The median follow-up time was 68 months (range 19–132 months). CONCLUSION: Renal biopsies in large renal masses may aid in preventing unnecessary surgery, especially in situations where imaging findings are equivocal or in patients with many comorbidities.
format Online
Article
Text
id pubmed-10474854
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104748542023-09-03 The Utility of Renal Mass Biopsy in Large Renal Masses Chau, Matthew Thia, Ivan Saluja, Manmeet Res Rep Urol Original Research OBJECTIVES: The role of needle core renal biopsy in large renal masses, defined as lesions larger than 4 cm, is debatable, as larger renal masses are associated with malignant histology. We aim to review the safety and impact of renal biopsy on the management of large renal masses. METHODS: A retrospective, single-center review of all renal biopsies performed between January 2011 and December 2020 at Royal Perth Hospital was conducted. Indications for biopsy, complications and final management plans were correlated to assess the value of biopsies in large renal masses. RESULTS: In total, 126 biopsies were performed. Indeterminate imaging findings and comorbidities were the main indications for biopsies. We identified 116 (92.1%) diagnostic biopsies and 10 (8.0%) non-diagnostic biopsies due to insufficient samples or inflammatory tissue. Of the diagnostic biopsies, 99 (78.6%) were malignant and 17 (13.5%) were benign. Unnecessary extirpative surgery was avoided in 17 patients. Histology included renal cell carcinoma (96%) and other malignancies such as urothelial carcinoma (3%) and non-Hodgkin’s lymphoma (1%). Benign biopsies identified histology including angiomyolipoma (35.3%) and oncocytoma (52.5%). The median follow-up time was 68 months (range 19–132 months). CONCLUSION: Renal biopsies in large renal masses may aid in preventing unnecessary surgery, especially in situations where imaging findings are equivocal or in patients with many comorbidities. Dove 2023-08-29 /pmc/articles/PMC10474854/ /pubmed/37663006 http://dx.doi.org/10.2147/RRU.S404998 Text en © 2023 Chau et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chau, Matthew
Thia, Ivan
Saluja, Manmeet
The Utility of Renal Mass Biopsy in Large Renal Masses
title The Utility of Renal Mass Biopsy in Large Renal Masses
title_full The Utility of Renal Mass Biopsy in Large Renal Masses
title_fullStr The Utility of Renal Mass Biopsy in Large Renal Masses
title_full_unstemmed The Utility of Renal Mass Biopsy in Large Renal Masses
title_short The Utility of Renal Mass Biopsy in Large Renal Masses
title_sort utility of renal mass biopsy in large renal masses
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474854/
https://www.ncbi.nlm.nih.gov/pubmed/37663006
http://dx.doi.org/10.2147/RRU.S404998
work_keys_str_mv AT chaumatthew theutilityofrenalmassbiopsyinlargerenalmasses
AT thiaivan theutilityofrenalmassbiopsyinlargerenalmasses
AT salujamanmeet theutilityofrenalmassbiopsyinlargerenalmasses
AT chaumatthew utilityofrenalmassbiopsyinlargerenalmasses
AT thiaivan utilityofrenalmassbiopsyinlargerenalmasses
AT salujamanmeet utilityofrenalmassbiopsyinlargerenalmasses